Skip to main content
. Author manuscript; available in PMC: 2009 Jun 30.
Published in final edited form as: Exp Dermatol. 2009 Feb 19;18(7):643–649. doi: 10.1111/j.1600-0625.2009.00841.x

Figure 5. PPARβ/δ activator GW501516 inhibited the decrease in filaggrin and involucrin, but not loricrin expression, on GC- treated murine epidermis.

Figure 5

Application of the PPARβ/δ activator GW501516 (4mM) on GC-treated murine epidermis normalized the levels of two keratinocyte differentiation markers, filaggrin (FIL) and involucrin (INV). However, this PPARβ/δ ligand did not prevent the decrease in loricrin (LOR) after GC treatment. N= 3.